about
The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative ReviewWhen 1+1>2: Nanostructured composites for hard tissue engineering applicationsCytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.Protein calorie malnutrition, nutritional intervention and personalized cancer care.Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese MiceChimeric fusion proteins used for therapy: indications, mechanisms, and safety.The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Severe Enteropathy and Hypogammaglobulinemia Complicating Refractory Mycobacterium tuberculosis Complex Disseminated Disease in a Child with IL-12Rβ1 Deficiency.Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Immunotherapy for Dogs: Running Behind Humans.Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling.
P2860
Q26768281-44157DF8-505E-4483-B105-190B551395F7Q30368848-5D7E711F-61B7-43A6-87FA-A459960A9031Q30381154-726CA639-FAB3-4DC7-9E95-57B2F9BC4DACQ33618955-F0E134B6-B592-4084-B726-C45FF4D70463Q35982905-3C8E586E-52AA-4800-A551-91984AE4B48DQ38400396-EDDB71A9-D9E1-44BC-909A-2DFC0E846339Q38677185-AC1C5093-9D86-419B-ACF6-A7EEBAC01F64Q38709455-B420BDD4-8739-48DD-9645-5B851FDC1464Q38968266-61B14F96-5D61-48F1-9386-757B33BAFC04Q40069916-81D7396A-D748-4794-A24A-F3DEA074FF54Q40124877-BE70EC2E-DFDC-4BB1-8A6A-872BE7956A2BQ47277628-7FDA5AC9-5A86-4E2D-98EB-BD43DC211597Q49829334-8E2FDF5A-7D29-4B01-B254-E6691A93814FQ50535273-D0234D30-FD08-496C-B882-9DE73B498496Q50963822-BC6DDB25-0EDD-448F-8C4F-D4FC1AC4A81C
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Side effects of cytokines approved for therapy.
@en
type
label
Side effects of cytokines approved for therapy.
@en
prefLabel
Side effects of cytokines approved for therapy.
@en
P2860
P1433
P1476
Side effects of cytokines approved for therapy.
@en
P2093
Brian A Baldo
P2860
P2888
P304
P356
10.1007/S40264-014-0226-Z
P577
2014-11-01T00:00:00Z
P6179
1013609891